|
Sunday November 08 2009 | Biotechnology feed | All feeds
|
|
|
Return to introduction on drug discovery ~ LeadDiscovery Reports Stimulating Munc1-13 as a means of increasing insulin release According to WHO, there are
some 130 million diagnosed diabetics in the world, a figure that is predicted
to increase to 300 million by 2025. The market for diabetes therapeutics is
also rising with global sales reportedly topping $8.1 billion for the 12
months to September 2000, a 19% increase over the previous 12 months (for
a full analysis of diabetes therapeutics and market opportunities click here).
Oral antidiabetic drugs, the leading class of drugs used to treat the disease,
accounted for almost 63% of sales during this period, while sales of insulin,
to which many diabetics must resort as a treatment option with time, stand at
around 30%. Further increases are inevitable and the market for diabetes
medications could exceed $20 billion by 2006.
LeadDiscovery and BioPortfolio aims to provide reliable, insightful analysis on the biotechnology industry. However, this information is provided "as is" and no representations or warranties either express or implied of completeness, accuracy, or of any other nature are made with respect to this information. This information is neither an offer to sell nor a solicitation to buy the securities of any company. This information contains forward-looking statements, which involve risks and uncertainties which may not be listed. The biotechnology industry is an emerging industry and the securities of the companies mentioned in this report have a very high degree of risk and volatility. For this reason, this information is supplied on the condition that the reader will make his or her own determination as to its suitability for any purpose prior to any use of this information. The employees and officers of LeadDiscovery and BioPortfolio may hold positions in some or all of the stocks discussed in this report. This abstract has been produced by LeadDiscovery Ltd. Founded by life scientists for life scientists we aim to help industry identify cutting edge drug discovery options and academic/biotech institutions maximize the potential of their research. Abstracts strictly reflect the opinion of LeadDiscovery's editorial panel. While all reasonable efforts are made to ensure the accuracy of information provided LeadDiscovery and the publisher BioPortfolio, takes no responsibility for incorrect or misleading information. LeadDiscovery is designed for educational and drug development purposes only and is not intended or designed to offer medical advice or advice of any sort, and must not be used for such purpose. The information provided through LeadDiscovery and BioPortfolio should not be used for diagnosing or treating a health problem or a disease and no reliance should be placed on any information contained in this abstract or elsewhere on LeadDiscovery's and BioPortfolio's website. It is not intended to be a substitute for professional care. If you have or suspect you may have a health problem, you should consult your physician or other health care provider. |
|
|